At chromosome 6q25.1, the estrogen receptor alpha gene ESR1 sits next to CCDC170 (Coiled-Coil Domain Containing 170), a gene whose protein organizes the Golgi apparatus and its microtubule connections inside cells. This locus is one of the most intensively studied regions in cancer and reproductive genetics — it has been implicated in breast cancer, endometriosis, and bone mineral density across dozens of GWAS studies spanning multiple ancestries.

rs9383935 is a variant in the 3' untranslated region (3' UTR) of CCDC170. Unlike the intronic rs1971256 also at this locus, which likely acts as a regulatory tag variant, rs9383935 has a defined molecular mechanism: the T allele disrupts a binding site for microRNA-27a (miR-27a), reducing the ability of miR-27a to bind and stabilize CCDC170 mRNA, and consequently lowering CCDC170 protein levels. The variant is in high linkage disequilibrium¹¹ linkage disequilibrium
variants in LD tend to be inherited together; r² = 0.86 here means they co-occur ~86% of the time with the classic GWAS sentinel rs2046210 upstream of ESR1, but shows a strong independent effect in conditional analysis.

The Mechanism

rs9383935 sits at GRCh38 position chr6:151,618,713 in the 3' UTR of CCDC170, the last segment of CCDC170 mRNA that is not translated into protein. This region typically contains binding sites for microRNAs — small RNAs that bind mRNAs and regulate how much protein is made.

The C allele (common) preserves a functional miR-27a binding site, allowing miR-27a to help maintain CCDC170 mRNA. The T allele disrupts this binding site. Luciferase reporter assays in MCF-7 and BT-474 breast cancer cell lines²² Luciferase reporter assays in MCF-7 and BT-474 breast cancer cell lines
Wang et al. Breast Cancer Research, 2014 demonstrated that constructs carrying the T allele had significantly lower reporter activity than the C allele constructs — confirming that the T allele reduces effective CCDC170 expression. Real-time qRT-PCR in patient samples confirmed the correlation between rs9383935 genotypes and CCDC170 mRNA levels.

CCDC170 protein localizes to the Golgi apparatus and organizes perinuclear microtubule networks³³ perinuclear microtubule networks
microtubules radiating from the Golgi help polarize cells and direct protein secretion; when disrupted, cells lose the ability to migrate in an organized, directional way. In cancer-associated truncation models, loss of CCDC170 Golgi localization drives increased cell motility and anchorage-independent growth — processes that contribute to tumor cell invasion and metastasis. Reduced expression from the T allele likely tilts cells in a similar direction, through a partial loss-of-function mechanism rather than a complete deletion.

The Evidence

The primary evidence for rs9383935 comes from a 2014 study of 1,064 breast cancer cases and 1,073 controls in Chinese women⁴⁴ 2014 study of 1,064 breast cancer cases and 1,073 controls in Chinese women
Wang et al. Breast Cancer Research. Breast cancer risk was significantly associated with rs9383935-T with an odds ratio of 1.38 (95% CI 1.20–1.57, P = 2.21×10⁻⁶). This effect was identified by conditional analysis as independent of rs2046210 — the two variants tag distinct molecular mechanisms at the same locus (ESR1 transcription regulation vs. CCDC170 mRNA stability). The study is moderately sized for GWAS standards, and the evidence level is moderate pending replication in larger multi-ethnic cohorts for rs9383935 specifically.

The broader locus has been comprehensively characterized. Fine-mapping in more than 118,000 subjects⁵⁵ Fine-mapping in more than 118,000 subjects
Dunning et al. Nature Genetics, 2016 identified at least five independent causal variants at 6q25, each regulating ESR1, RMND1, or CCDC170 through distinct enhancer elements. The CCDC170/ESR1 locus is also one of the most robustly replicated endometriosis susceptibility regions: a meta-analysis of 17,045 cases and 191,596 controls⁶⁶ meta-analysis of 17,045 cases and 191,596 controls
Sapkota et al. Nature Communications, 2017 and the largest endometriosis GWAS to date in 60,674 cases⁷⁷ largest endometriosis GWAS to date in 60,674 cases
Rahmioglu et al. Nature Genetics, 2023 both confirm genome-wide significance for this region in endometriosis.

The T allele of rs9383935 is notably more common in East Asian populations (~30%) than in Europeans (~8%) or Africans (~5%), consistent with the stronger breast cancer associations initially detected in Chinese cohorts.

Practical Actions

Lower CCDC170 expression from the T allele creates two clinically relevant contexts:

For breast cancer risk, CT and TT carriers at this locus have elevated susceptibility, particularly for estrogen receptor-positive (ER+) subtypes given the co-regulatory environment at this locus. Proactive surveillance — staying current with breast cancer screening guidelines and discussing cumulative polygenic risk with a clinician — is the primary actionable step, especially when combined with risk alleles at the linked rs2046210 (ESR1 promoter) and rs1971256 (CCDC170 intron) loci.

For endometriosis, the locus context matters: rs9383935 sits within the same 6q25.1 regulatory block as rs1971256 and rs2046210, both of which have stronger independent evidence for endometriosis susceptibility. Women carrying the T allele at rs9383935 — particularly alongside risk alleles at those neighbors — are in a portion of the population with elevated estrogen-signaling genetic burden from this chromosome region.

Interactions

rs1971256 (CCDC170 intron 1) and rs2046210 (ESR1 upstream): These two variants are already characterized in the database and sit at the same 6q25.1 locus. rs9383935 adds a third independent molecular mechanism: 3' UTR mRNA regulation of CCDC170 itself (as distinct from rs1971256's intronic tagging effect and rs2046210's ESR1 transcription regulation). Women carrying risk alleles at all three variants face compounded molecular disruption of the CCDC170-ESR1 co-regulatory axis.

rs9340799 (ESR1 XbaI): The classical ESR1 polymorphism rs9340799, characterized in the reproductive_hormones and endometriosis categories, is also at 6q25.1. Compound carriers of rs9383935-T and rs9340799-G have both reduced CCDC170 expression (via disrupted miR-27a binding) and altered ESR1 XbaI signaling. The 6q25.1 block compound action for women carrying multiple risk alleles is proposed in the harvesting notes.

The MTRR gene (methionine synthase reductase) encodes the enzyme responsible for keeping methionine synthase (MTR) operational. MTR converts homocysteine to methionine using methylcobalamin ¹¹ The methyl-carrying, active form of vitamin B12 (active B12) as a cofactor, but during each catalytic cycle B12 becomes oxidized and inactive. MTRR reactivates it, sustaining the methylation cycle that underpins DNA synthesis, neurotransmitter regulation, and epigenetic gene control. Disruptions to MTRR function allow homocysteine to accumulate and SAM (the universal methyl donor) to fall — outcomes with consequences in developing embryos that are especially dependent on tight methylation control.

rs1802059 (c.1911G>A) is a synonymous change that does not alter the amino acid at position 637 (p.Ala637=), so it is classified as benign by ClinVar for hereditary B12 deficiency. Yet two independent Han Chinese case-control studies have found the A allele associated with substantially elevated congenital heart disease (CHD) risk in offspring — the homozygous AA genotype carrying a five- to nearly four-fold increased odds in one study and the maternal carrier analysis respectively. This is a classic example of a synonymous variant that may influence splicing efficiency, mRNA stability, or co-translational folding without producing a detectable amino acid change, but whose downstream effect on MTRR activity matters most during embryonic cardiac development.

The Mechanism

Synonymous variants in coding regions are not functionally silent. They can alter exonic splicing enhancer or silencer sequences, change local mRNA secondary structure, or shift the codon usage to a rarer tRNA that slows translation elongation at critical co-translational folding points. For rs1802059 specifically, no biochemical or cell-line functional study has yet isolated the mechanism — but the epidemiological signal is consistent across two independent Han Chinese cohorts and biologically coherent: reduced MTRR activity impairs B12-dependent homocysteine remethylation, and the embryonic heart is among the most epigenetically sensitive tissues during organogenesis. The CHD associations parallel those seen for other functional MTRR variants (rs10380 His595Tyr, OR 2.27; rs1532268, aOR 3.18), suggesting the gene as a whole is a meaningful node in cardiac developmental risk.

The Evidence

The primary evidence comes from two complementary hospital-based case-control studies in Han Chinese populations. Wei et al. 2023²² Wei et al. 2023
Wei J et al. Maternal MTRR gene polymorphisms and CHD risk. J Matern Fetal Neonatal Med, 2023 studied 740 mothers of CHD-affected children versus 683 healthy controls and found that the maternal G/A genotype carried aOR 1.41 and A/A genotype aOR 3.95 for offspring CHD. Seven MTRR haplotypes — combinations including rs1802059 — showed statistically significant associations with CHD occurrence. Li et al. 2024³³ Li et al. 2024
Li L et al. Maternal folic acid supplementation and offspring MTRR polymorphism and CHD. J Health Popul Nutr, 2024 analyzed 595 CHD-affected children and 605 healthy child controls, finding that the offspring AA genotype carried OR 5.13 (95% CI 2.15–12.23) and GA OR 1.81 (95% CI 1.35–2.43) compared to GG. Crucially, the interaction term between maternal folic acid supplementation and rs1802059 variant status was significant at OR 0.38 (95% CI 0.15–0.94) — meaning that among offspring carrying the A allele, maternal folic acid supplementation substantially reduced CHD risk.

The evidence level is emerging: both studies are case-control designs in a single ethnic group, functional mechanism has not been biochemically confirmed, and replication in non-Han populations has not been reported. The effect sizes are nonetheless striking and the folic acid interaction is highly clinically relevant.

Practical Implications

The strong interaction between maternal folic acid supplementation and the rs1802059 risk genotype is the most actionable finding. This variant is in MTRR — the B12 recycling enzyme. The standard methylation cycle intervention toolkit applies: methylfolate (bypassing any MTHFR conversion bottleneck), active B12 forms (methylcobalamin or hydroxocobalamin to reduce dependence on MTRR recycling), and homocysteine monitoring as a functional readout. Periconceptional supplementation is the highest-priority action for individuals planning pregnancy. Outside of pregnancy, maintaining adequate one-carbon cycle cofactors reduces the downstream consequences of any impaired MTRR recycling capacity.

Interactions

rs1802059 sits within MTRR alongside three other functionally characterized variants: rs1801394 (A66G, p.Ile22Met — reduces enzyme efficiency), rs10380 (His595Tyr — impairs B12 reactivation chemistry), and rs162049 (intronic — reduces MTRR protein expression). Carrying multiple MTRR risk alleles compounds the reduction in B12 recycling capacity. The most clinically relevant interaction is with MTHFR C677T (rs1801133): impaired methylfolate supply combined with impaired B12 recycling creates dual pressure on the homocysteine remethylation pathway that neither variant alone produces.

Interleukin-4¹¹ Interleukin-4
IL-4 is the master switch cytokine for Th2 immune responses — it drives IgE class switching in B cells, mast cell activation, and alternative macrophage polarization acts through a dimeric receptor on the surface of immune cells. The alpha chain of this receptor (IL-4Rα, encoded by IL4R on chromosome 16) is the critical ligand-binding component shared by both the type I receptor (IL-4Rα + γc, on lymphocytes) and the type II receptor (IL-4Rα + IL-13Rα1, on non-hematopoietic cells). The rs1805010 variant changes the amino acid at position 75 in the receptor's extracellular IL-4–binding domain from isoleucine (Ile, the common form) to valine (Val), subtly reshaping the interface where IL-4 engages its receptor. In large patient studies, this variant is found in 80% of allergic bronchopulmonary aspergillosis patients²² 80% of allergic bronchopulmonary aspergillosis patients
Knutsen et al. Clin Mol Allergy 2006; 62 ABPA patients (40 cystic fibrosis + 22 asthmatic) vs 56 non-ABPA controls; IL-4Rα SNPs overall found in 95% of ABPA cases, making it the most prevalent genetic risk marker for this severe fungal allergy syndrome.

The Mechanism

The Val75 substitution is located in the extracellular domain of IL-4Rα, within the region that contacts the IL-4 cytokine directly. Although the amino acid change is chemically conservative (isoleucine and valine differ only by a single methylene group), functional studies consistently find that Val75 cells show heightened responsiveness to IL-4 stimulation — producing more surface CD23 (the low-affinity IgE receptor) per B cell at equivalent IL-4 concentrations compared to Ile75 B cells. Khan et al. 2000³³ Khan et al. 2000
International Archives of Allergy and Immunology 2000; 10 ABPA patients, 9 atopic controls, 8 non-atopic controls; ABPA patients showed significantly greater CD23 and CD86 upregulation after IL-4 stimulation at 5 and 10 ng/mL (p<0.001) established that IL-4 hypersensitivity is a defining immunological feature of ABPA, and the Ile75Val variant provides the structural basis for this amplified receptor output. Through the JAK-STAT6 signaling cascade downstream of IL-4Rα, Val75 carriers experience enhanced STAT6 phosphorylation, greater transcription of IgE switch factors (AID, germline ε transcript), and higher steady-state serum IgE — exactly the physiological conditions that predispose to ABPA and severe asthma.

The Evidence

The most direct evidence linking rs1805010 to ABPA comes from Knutsen et al. (2006), who found ile75val present in 80% of ABPA patients⁴⁴ ile75val present in 80% of ABPA patients
Clin Mol Allergy 2006; n=62 ABPA, n=56 non-ABPA controls; CD23 expression significantly elevated after IL-4 stimulation in ABPA patients at 5 and 10 ng/mL, p<0.02 — a prevalence far exceeding population background frequencies. In asthma more broadly, Al-Muhsen et al. 2014⁵⁵ Al-Muhsen et al. 2014
case-control study, 190 severe asthmatics vs 194 controls, Saudi Arabia; G allele OR=1.6 (95% CI 1.01–2.53) for asthma susceptibility; combined G-G haplotype with rs1801275 OR=2.43 confirmed rs1805010 G allele as a significant asthma susceptibility factor, with notably stronger effects in females (OR=3.73). Chinese pediatric data from Chen et al. 2014⁶⁶ Chen et al. 2014
160 asthmatic children vs 143 healthy controls; I75V variant allele carriers had significantly higher serum IgE vs non-carriers in the asthma group (p=0.036) confirmed that carrying the Val75 allele associates with higher IgE production, providing a direct biological link between the genotype and the IgE-mediated pathology in both asthma and ABPA. Occupational allergen studies reinforce this: in 373 bakery workers⁷⁷ 373 bakery workers
Omae et al. 2013; G allele carriers had 16.0% prevalence of work-related lower respiratory symptoms vs 2.9% in AA carriers, p=0.004, the Val75 allele significantly amplified the response to inhaled allergens.

Practical Implications

Carriers of the Val75 (G) allele — particularly GG homozygotes — have an inherently lower threshold for IL-4–driven immune activation. In clinical practice this means: monitoring serum total IgE as a direct readout of IL-4Rα activity; heightened vigilance for fungal sensitization (especially Aspergillus fumigatus) in asthmatics, given the 80% ABPA prevalence of this allele; and recognition that the JAK-STAT6 pathway downstream of IL-4Rα is the pharmacological target of dupilumab (anti-IL-4Rα). Val75 carriers with moderate-severe asthma or atopic dermatitis unresponsive to inhaled corticosteroids are biologically well-aligned with dupilumab therapy, since the drug targets the exact receptor whose activity is enhanced by this variant.

Interactions

rs1805010 (Ile75Val) and rs1801275 (Gln576Arg, Q576R) are the two most clinically studied IL4R variants and act synergistically. Ile75Val sits in the extracellular IL-4–binding domain and increases ligand-binding sensitivity; Q576R sits in the cytoplasmic signaling domain and amplifies downstream JAK1-STAT6 phosphorylation (the Hershey 1997 NEJM gain-of-function variant). Carriers of both risk alleles simultaneously — the G-G haplotype — face compounding IL-4 pathway amplification at two mechanistically distinct levels: enhanced IL-4 capture at the extracellular surface AND amplified intracellular signal transduction. The G-G haplotype is more frequent in severe asthmatics than either variant alone (OR=2.43). The combination also appears at increased frequency in ABPA patients alongside IL-13 polymorphisms (rs20541 Arg130Gln), since IL-13 shares the IL-4Rα subunit in the type II receptor — making the rs1805010 × rs1801275 × rs20541 triad the most biologically coherent gene-gene interaction in ABPA genetics.

The amyloid precursor protein (APP) gene encodes a large transmembrane protein whose sequential cleavage by beta-secretase (BACE1)¹¹ beta-secretase (BACE1)
The enzyme that makes the first cut in APP, releasing the C99 fragment that is subsequently cleaved by gamma-secretase to produce amyloid-beta peptides and gamma-secretase generates the amyloid-beta (Aβ) peptides central to Alzheimer's disease pathology. Most pathogenic APP mutations cluster around the cleavage sites and accelerate Aβ production; most operate via autosomal dominant inheritance.

The A673V variant is an exception on both counts. Discovered in 2009 in an Italian family by Di Fede et al.²² Di Fede et al.
A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science 2009;323:1473–7, A673V follows strict autosomal recessive inheritance — disease occurs only when both APP copies carry the mutation. Heterozygous relatives who carry a single copy remain cognitively unaffected. This unusual pattern arises because the mutant Aβ peptide interferes with the aggregation of normal wild-type Aβ, creating a dominant-negative protective effect that is lost when no wild-type peptide is present (i.e., in homozygotes).

The Mechanism

Position 673 in the APP protein (position 2 in the Aβ peptide, hence the alternative designation Aβ A2V) sits immediately adjacent to the BACE1 beta-secretase cleavage site. The A673V substitution changes an alanine to a valine at this critical junction, with two consequences that differ dramatically based on gene dosage.

In the homozygous state, Zhang et al. 2017³³ Zhang et al. 2017
BACE1 Cleavage Site Selection Critical for Amyloidogenesis. J Neurosci 2017;37:6915–25 showed that A673V shifts BACE1 preferential cleavage from the Glu11 site to the Asp1 site, markedly elevating the amyloidogenic C99/C89 ratio and driving excess Aβ production. The mutant A2V-Aβ peptide then forms oligomers with a distinctive polymer-network morphology — connecting hydrophobic residues on external surfaces — that is more aggregation-prone than wild-type, leading to accelerated fibrillization and neurotoxicity.

In the heterozygous state, something remarkable occurs: when A2V-mutant and wild-type Aβ peptides co-exist, Messa et al. 2014⁴⁴ Messa et al. 2014
J Biol Chem 2014;289:24143–52 demonstrated that the mixed assemblies form structures nearly identical to wild-type aggregates, but with slower kinetics (characteristic time τ = 3 hours versus 1.5 hours for pure A2V and 6.7 hours for wild-type). Di Fede et al. showed that co-incubation "conferred instability on Aβ aggregates and inhibited amyloidogenesis and neurotoxicity," explaining why one normal APP allele fully protects carriers despite the presence of the pathogenic A2V peptide.

The neuropathological fingerprint is distinctive. Giaccone et al. 2010⁵⁵ Giaccone et al. 2010
Acta Neuropathol 2010;120:803–12 documented extensive amyloid deposition in homozygous brain tissue with an atypical topographic pattern: cerebellar involvement was pronounced and the striatum was relatively spared — the opposite of the hierarchical spread seen in sporadic Alzheimer's disease. Cerebrovascular amyloid deposition was particularly prominent.

The Evidence

The original Di Fede et al. 2009 Science paper⁶⁶ Di Fede et al. 2009 Science paper identified A673V in a proband with early-onset Alzheimer-type dementia and her younger sister showing initial cognitive decline — both homozygous. Multiple heterozygous relatives in the same family were examined and found to be cognitively unaffected, establishing the recessive Mendelian pattern.

The variant is vanishingly rare: the A allele was not observed in any of 478 alleles in the ALFA database. It appears primarily in Italian families, with only a handful of homozygous cases documented in the world literature. ClinVar (variation ID 18106) classifies it as pathogenic for Alzheimer disease based on OMIM-curated evidence (SCV000040032.2).

The dominant-negative anti-amyloidogenic effect of the heterozygous state has inspired a therapeutic direction. Cimini et al. 2016⁷⁷ Cimini et al. 2016 developed a cell-permeable fusion peptide (Aβ1-6A2VTAT(D)) that mimics the heterozygous protective state, showing reversal of Aβ1-42-induced synaptopathy in both cell culture and mouse models. This line of research remains in early-stage preclinical development.

Practical Actions

For heterozygous carriers (AG genotype): the recessive mechanism means your single A allele does not elevate your personal Alzheimer's risk above population baseline. The clinical relevance is entirely reproductive — two carrier parents have a 25% chance per pregnancy of producing a homozygous child. Genetic counselling before conceiving and partner testing resolve the actual risk.

For homozygous individuals (AA genotype): this is a severe early-onset Alzheimer's disease genotype. Cognitive and neurological assessment with a specialist in neurodegenerative disease is indicated immediately. Clinical genetic counselling for the individual and family members is essential.

Interactions

The most important clinical interaction at this locus is the contrast with rs63750847 (APP A673T, the Icelandic protective variant). Both variants affect the identical codon — A673T substitutes threonine and is associated with ~50% reduced Alzheimer's risk, while A673V substitutes valine and causes recessive disease. The opposing consequences of two different substitutions at the same nucleotide position illustrate how precisely BACE1 substrate recognition can be tuned by single amino acid changes.

APOE4 (rs429358) modifies risk for sporadic Alzheimer's disease and could theoretically act as a modifier for the rate or severity of amyloid accumulation in the unusual context of a homozygous A673V carrier, though no direct clinical data on this compound situation exists given the extreme rarity of A673V homozygotes.

The insulin receptor (INSR) does far more than regulate blood sugar. Expressed in neurons throughout the brain — particularly in the hippocampus, hypothalamus, and prefrontal cortex — the insulin receptor plays a role in synaptic plasticity¹¹ synaptic plasticity
The strengthening or weakening of synaptic connections in response to activity; essential for memory formation and learning, dopamine signaling, and neuronal survival. When insulin receptor signaling is impaired in the brain, the consequences extend well beyond glycemia into cognitive function and psychiatric vulnerability.

rs2229431 is a synonymous variant in exon 13 of INSR — meaning the DNA sequence changes but the encoded amino acid (asparagine at position 865) does not. The variant is classified as benign by ClinVar in the context of classic insulin receptor disorders (leprechaunism, Rabson-Mendenhall syndrome). However, synonymous variants are not necessarily functionally silent: they can alter mRNA splicing efficiency²² mRNA splicing efficiency
The process of removing introns from pre-mRNA; synonymous variants near splice sites or in exonic splicing enhancers can shift the ratio of alternatively spliced isoforms, mRNA stability, and translational kinetics. Exon 13 encodes part of the region that contributes to the intracellular beta subunit involved in tyrosine kinase autophosphorylation³³ tyrosine kinase autophosphorylation
The process by which the insulin receptor activates itself by adding phosphate groups to its own tyrosine residues; the initiating step of intracellular insulin signaling.

The Mechanism

INSR produces two splice isoforms — INSR-A (exon 11 excluded) and INSR-B (exon 11 included) — that differ in their affinity for insulin, insulin-like growth factor 2 (IGF-2), and other ligands. INSR-A predominates in neurons and fetal tissues; INSR-B predominates in the liver and skeletal muscle. Exon 13 encodes a segment of the intracellular beta subunit that participates in tyrosine kinase domain assembly⁴⁴ tyrosine kinase domain assembly
The region of INSR that executes the first steps of insulin signaling by phosphorylating downstream adaptor proteins including IRS-1 and IRS-2. A synonymous change in this exon could in principle alter local mRNA secondary structure, affect ribosomal elongation pausing, or subtly shift the ratio of correctly folded receptor at the cell surface. The precise molecular consequence of this specific variant has not been characterized in mechanistic studies.

The Evidence

The primary evidence linking rs2229431 to phenotype comes from two small studies by Melkersson and colleagues, both examining INSR gene variants in Swedish psychiatric cohorts.

Melkersson 2018⁵⁵ Melkersson 2018
Sequencing of the insulin receptor (INSR) gene reveals association between gene variants in exon and intron 13 and schizoaffective disorder. Neuro Endocrinol Lett, 2018 sequenced the complete INSR gene in 105 patients with schizophrenia or schizoaffective disorder and 60 controls. rs2229431 showed significant differences in genotype distribution between the three groups — but the association was driven specifically by schizoaffective disorder patients, who differed from both schizophrenia patients and controls. No specific p-values or odds ratios were reported in the abstract.

Melkersson & Persson 2023⁶⁶ Melkersson & Persson 2023
Associations between heredity, height, BMI, diabetes mellitus type 1 or 2 and gene variants in the insulin receptor (INSR) gene in patients with schizophrenia. Neuro Endocrinol Lett, 2023 followed up in 94 schizophrenia patients and 60 controls, identifying 50 INSR variants. Overall, no significant differences were found between all patients and controls, but in subgroup analysis rs2229431 tended to associate with family history of schizophrenia and significantly associated with height among patients.

A GWAS Catalog association also links the A allele to body height (beta = 0.0109 SDs, p = 7×10⁻¹⁵), a pleiotropic signal consistent with INSR's role in growth factor signaling during development. This height association provides independent evidence that the variant is not entirely neutral.

The evidence base is limited: two studies from a single research group, small sample sizes, no replication in independent cohorts, and no mechanistic characterization of the variant's molecular effect. This is firmly emerging-level evidence.

Practical Actions

For carriers of the A allele, the current evidence does not support any specific clinical intervention. The psychiatric associations require replication before clinical translation. What is actionable is ensuring that brain insulin signaling is optimally supported through lifestyle factors known to maintain insulin receptor sensitivity in neural tissue — particularly aerobic fitness and limiting chronic hyperglycemia, both of which independently modulate brain insulin receptor expression.

Given INSR's dual metabolic and neurological roles, carriers of the A allele have reason to monitor both metabolic health (fasting glucose, insulin) and cognitive health over time, and to discuss any family history of mood or psychotic disorders with a clinician.

Interactions

The intron 13 variant rs12610022, also identified by Melkersson 2018, showed near-significant differences in the same schizoaffective cohort — suggesting that the exon 13 and intron 13 regions of INSR may together form a functional haplotype relevant to neural insulin receptor expression or activity. The broader INSR gene context includes interactions with insulin signaling pathway components including IRS-1 (rs1801278) and IRS-2, though no compound heterozygosity data exist for rs2229431 specifically.

Your heart produces its own protective signaling molecules. CYP2J2 is a cytochrome P450 enzyme expressed primarily in cardiac myocytes and vascular endothelial cells, where it converts arachidonic acid into epoxyeicosatrienoic acids (EETs)¹¹ epoxyeicosatrienoic acids (EETs)
Biologically active lipid mediators with vasodilatory, anti-inflammatory, and cardioprotective properties. These EETs — particularly 11,12-EET and 14,15-EET — relax blood vessel walls, suppress vascular inflammation, inhibit platelet aggregation, and protect cardiac tissue from ischemic injury. When CYP2J2 activity is reduced, EET levels fall and this local cardioprotective system is compromised.

rs2280275 is an intronic variant in CYP2J2 that lies in strong linkage disequilibrium²² linkage disequilibrium
Alleles in LD are inherited together so frequently that one can serve as a proxy for the other, even without a direct functional role with the promoter variant rs890293 (CYP2J2*7). That promoter variant disrupts a Sp1 transcription factor binding site and reduces CYP2J2 promoter activity by approximately 50%, leading to measurably lower plasma EET concentrations. rs2280275 is therefore a marker for — and likely a contributing modifier of — reduced CYP2J2-mediated EET biosynthesis.

The Mechanism

CYP2J2 sits at the intersection of two metabolic programmes. Its primary endogenous role is epoxygenating polyunsaturated fatty acids: arachidonic acid yields EETs, EPA yields epoxyeicosatetraenoic acids (EEQs)³³ epoxyeicosatetraenoic acids (EEQs)
17,18-EEQ is the predominant omega-3 epoxide from EPA metabolism by CYP2J2, with potent antiarrhythmic properties, and DHA yields epoxydocosapentaenoic acids (EDPs). These omega-3-derived epoxides are actually preferred CYP2J2 substrates — EPA is metabolized at roughly 17-fold higher efficiency than arachidonic acid. This substrate competition means that dietary omega-3 intake can partially compensate for reduced CYP2J2 activity by flooding the enzyme with alternative substrates and shifting the eicosanoid profile toward cardioprotective mediators. Its secondary role is xenobiotic metabolism: CYP2J2 metabolizes antihistamines including astemizole, ebastine, and terfenadine in the heart.

The Evidence

The landmark 2004 Spiecker et al. Circulation study⁴⁴ 2004 Spiecker et al. Circulation study
Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2 established that the CYP2J2*7 (rs890293) promoter variant, which is in strong LD with rs2280275, was present in 17.3% of CAD patients versus 10.6% of controls (OR 2.23, 95%CI 1.04–4.79) in a cohort of 289 CAD patients and 255 controls. Carriers had significantly lower plasma EET metabolite concentrations.

rs2280275 itself has been directly studied in several populations. A 2013 Chinese study of 336 Uygur CAD patients⁵⁵ 2013 Chinese study of 336 Uygur CAD patients
Zhu et al. A novel polymorphism of the CYP2J2 gene is associated with coronary artery disease found that the CC genotype (plus-strand T/T) was protective against CAD in men (dominant model OR 0.28, P=0.001), with the C allele (plus-strand C) showing a sex-specific risk pattern. A 2019 Russian study of 2,314 subjects⁶⁶ 2019 Russian study of 2,314 subjects
Polonikov et al. A comprehensive study revealed SNP-SNP interactions and sex-dependent relationship found rs2280275 associated with essential hypertension in women specifically (OR 1.59, 95%CI 1.10–2.37), replicated in an independent cohort. Notably, no association was found in men, underscoring a pronounced sex-dependent effect. Results differ across populations: Uygur and Russian studies show directionally opposite effects of the T allele (papers' notation) in hypertension versus CAD contexts, likely reflecting population differences in LD structure and modifier genes.

Practical Actions

The most actionable implication concerns dietary omega-3 intake. CYP2J2 processes EPA and DHA from fish oil more efficiently than it processes arachidonic acid, generating cardioprotective 17,18-EEQ and 19,20-EDP⁷⁷ cardioprotective 17,18-EEQ and 19,20-EDP
Antiarrhythmic omega-3 epoxides that activate cardiac potassium channels and reduce calcium-dependent arrhythmia triggers. Individuals carrying the C allele, whose EET-producing capacity may be reduced, have the most to gain from shifting the substrate pool toward omega-3 fatty acids through supplementation. Cardiovascular monitoring is also relevant: elevated blood pressure and standard lipid panel tracking are supported by the hypertension and CAD associations found across multiple populations.

Interactions

rs2280275 is in strong linkage disequilibrium with the CYP2J2 promoter variant rs890293 (CYP2J2*7). Studies of these two variants frequently find similar effect directions and magnitudes, and haplotype analyses suggest they tag the same underlying reduced-expression signal. The neighboring intronic SNP rs11572325 shows similar associations in the same Russian hypertension dataset, and all three variants appeared in the highest-risk female haplotype (T-T-G-C-C-C-T-A). The soluble epoxide hydrolase variant rs751141 (EPHX2) modulates the downstream degradation of EETs: reduced EPHX2 activity raises EET levels, which can partially offset reduced CYP2J2 production. The combined genotype pattern of rs2280275 and rs751141 has been examined in the context of diabetic nephropathy — their net effect on EET tone may be relevant when considering renal and cardiovascular risk together.

Pyridoxal 5'-phosphate (PLP) — the metabolically active form of vitamin B6 — is an essential cofactor for over 140 enzymes, including every enzyme involved in synthesizing the neurotransmitters that govern mood, cognition, and sleep: serotonin, dopamine, GABA, and melatonin. Before any of this biochemistry can happen, dietary vitamin B6 must be converted to PLP by PNPO¹¹ PNPO
Pyridoxamine 5'-phosphate oxidase — catalyzes the final oxidative step converting PNP and PMP to PLP, the active cofactor form of vitamin B6, a gatekeeper enzyme at the terminal step of B6 activation. rs2325751 sits 2 kilobases upstream of the PNPO coding sequence — a regulatory position where sequence variation can influence how much PNPO protein the gene produces without altering the protein's structure. Reduced PNPO expression would constrain PLP supply to the entire neurotransmitter network simultaneously.

The Mechanism

The rs2325751 T/G variant lies in the 5′-flanking region of PNPO, a location that commonly harbors promoter elements, transcription factor binding sites, and enhancer sequences that regulate gene transcription. While the functional consequence of this specific variant has not been characterized at the molecular level, 2-kb upstream variants frequently act by altering binding affinity for transcriptional activators or repressors — shifting the basal expression rate of the downstream gene. If the G allele reduces PNPO transcription, the downstream effects would be broad: lower PNPO enzyme activity, reduced conversion of pyridoxine 5'-phosphate and pyridoxamine 5'-phosphate to PLP, and consequently a reduced cofactor supply to all PLP-dependent enzymes in neurotransmitter biosynthesis.

This contrasts with the nearby missense variant rs17679445²² rs17679445
PNPO Arg116Gln — reduces catalytic efficiency of the PNPO enzyme itself rather than its expression level, which reduces enzyme catalytic efficiency rather than expression. Both variants ultimately impair PLP supply, but potentially through distinct molecular mechanisms that could act independently or additively.

A 2012 review³³ 2012 review
di Salvo ML et al. Biomedical aspects of pyridoxal 5'-phosphate availability. Front Biosci (Elite Ed), 2012 of PLP bioavailability noted that multifactorial neurological and psychiatric conditions — including schizophrenia, autism, Alzheimer's disease, and Parkinson's disease — all correlate with inadequate intracellular PLP levels, underscoring PNPO's role as a convergence point for neurological risk.

The Evidence

The variant's psychiatric association was identified in Song et al. 2007⁴⁴ Song et al. 2007
Song H et al. Association between PNPO and schizophrenia in the Japanese population. Schizophrenia Research, 2007, which genotyped 8 PNPO SNPs in 359 schizophrenia cases and 582 controls. Among all 8 markers, rs2325751 produced the strongest single-SNP association signal (p=0.004). Haplotype analysis across multiple PNPO markers strengthened the signal substantially (permutation p<0.00001), suggesting that the locus as a whole — not a single causal variant — carries schizophrenia risk. The study's biological hypothesis was direct: PNPO controls PLP synthesis, and PLP is required for both homocysteine metabolism and neurotransmitter synthesis, two pathways consistently implicated in schizophrenia pathology.

It is important to calibrate the evidence: this is a single study in a single population (Japanese), with no published replication in other populations. The association is statistically significant but has a modest sample size by modern GWAS standards, and rs2325751 has not appeared in large-scale cross-population schizophrenia GWAS. This places the finding squarely at the emerging evidence level — biologically plausible, statistically significant in one population, but not yet replicated.

The biological rationale is strengthened by independent lines of evidence. A 2017 meta-analysis⁵⁵ 2017 meta-analysis
Firth J et al. The effects of vitamin and mineral supplementation on symptoms of schizophrenia: a systematic review and meta-analysis. Psychol Med, 2017 of 18 randomized controlled trials found that B-vitamin supplementation (B6, B8, B12) reduced schizophrenia symptoms significantly more than placebo (g=0.508, 95% CI 0.01–1.01). A randomized trial by Levine et al. 2006⁶⁶ Levine et al. 2006
Levine J et al. Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biol Psychiatry, 2006 showed that combined folate/B12/B6 supplementation in 42 schizophrenia patients with elevated homocysteine significantly reduced both homocysteine and PANSS symptom scores. A Mendelian randomization meta-analysis by Ye et al. 2025⁷⁷ Mendelian randomization meta-analysis by Ye et al. 2025
Ye M et al. Causal relationship between B vitamins and neuropsychiatric disorders. Neurosci Biobehav Rev, 2025 found that genetically predicted higher vitamin B6 levels causally protect against schizophrenia, providing genetic-level evidence that the PLP pathway is relevant to schizophrenia risk.

Practical Actions

The key implication for GG carriers is the same bypass strategy used for rs17679445: since the upstream variant may reduce PNPO enzyme availability, using pyridoxal-5-phosphate (P5P) — the already-activated form of B6 — sidesteps any PNPO-related limitation entirely. P5P does not require PNPO conversion and enters cells directly as the bioactive cofactor.

Monitoring plasma PLP levels and homocysteine offers an objective way to assess whether a PNPO-affecting genotype is producing a measurable biochemical effect. Elevated homocysteine (> 10 μmol/L) alongside low plasma PLP (< 30 nmol/L) is a pattern consistent with impaired B6 activation.

Interactions

rs2325751 and rs17679445 are both in the PNPO gene (2 kb apart), and both affect PLP supply — the upstream variant potentially through reduced expression, the missense variant through reduced catalytic efficiency. Carriers of risk alleles at both positions would face compounded PLP limitation. No study has examined the combination, but the mechanistic overlap is direct: both variants converge on the same enzymatic output.

The homocysteine pathway is a second interaction axis. PLP is a required cofactor for cystathionine beta-synthase (CBS) and cystathionine gamma-lyase (CSE), the enzymes that clear homocysteine via the transsulfuration pathway. Impaired PNPO → reduced PLP → reduced CBS/CSE activity → elevated homocysteine. This creates a potential interaction with MTHFR variants (rs1801133) that independently elevate homocysteine through the remethylation pathway. Combined impairment of both routes would compound homocysteine elevation and the associated psychiatric risk.

PPARG (Peroxisome Proliferator-Activated Receptor Gamma) is a nuclear transcription factor that sits at the heart of adipocyte biology. It controls how preadipocytes differentiate into fat cells, regulates fatty acid storage and oxidation, and determines how well tissues respond to insulin. PPARG is also the molecular target of thiazolidinedione¹¹ thiazolidinedione
A class of insulin-sensitizing diabetes drugs including pioglitazone and rosiglitazone that work by directly activating PPARG diabetes medications. The rs2920502 variant lies within intron 1 of the PPARG gene at chromosome 3p25.2 and has emerged from both large-scale GWAS and population-specific association studies as a functional modifier of adipogenesis and glucose homeostasis.

The Mechanism

rs2920502 is classified as an intronic regulatory variant sitting within a region of PPARG that has long-range regulatory activity²² long-range regulatory activity
The GWAS Catalog classifies rs2920502 as a regulatory_region_variant influencing PPARG expression, not a coding change. The C allele of rs2920502 is thought to alter the local chromatin environment or transcription factor binding within PPARG intron 1, subtly shifting the transcriptional output of the gene. This mechanistic model is consistent with the PPARG locus having multiple independent regulatory variants (rs1801282 Pro12Ala, rs1175543, rs17036314) spread across the gene that each contribute to the same downstream phenotype — adipocyte differentiation capacity and insulin sensitivity.

Because PPARG drives adipogenesis (fat cell formation), variants that modestly increase PPARG expression or alter its transcriptional activity can tip the balance toward greater fat accumulation — particularly visceral and ectopic fat — and impaired insulin signaling. The C allele at rs2920502 appears to carry this adipogenic risk.

The Evidence

A large genome-wide association study identified rs2920502 as a significant locus for body fat percentage³³ body fat percentage
Association ID 132681528, GWAS Catalog; beta = +0.19 units per C allele, SE = 0.02 with a p-value of 3.0 × 10⁻¹⁷ — a genome-wide significant signal reflecting a consistent, replicable association between the C allele and higher body fat.

At the genotype level, Zhou et al. 2018⁴⁴ Zhou et al. 2018
Zhou et al. Uncoupling Protein 2 and Peroxisome Proliferator-Activated Receptor γ Gene Polymorphisms in Association with Diabetes Susceptibility. Int J Endocrinol, 2018 studied 589 Chinese Han subjects and found that the GG genotype conferred decreased risk of impaired glucose tolerance (OR 0.715, 95% CI 0.527–0.97, p=0.031) and was associated with better blood glucose control, increased insulin secretion, and lower HOMA-IR compared to GC/CC carriers. This positions C allele carriers as having a meaningful disadvantage in glucose metabolism.

Song et al. 2017⁵⁵ Song et al. 2017
Song et al. Association of gene variants of transcription factors PPARγ, RUNX2, Osterix genes and COL2A1, IGFBP3 genes with osteonecrosis of the femoral head. Bone, 2017 found that the CC genotype was significantly associated with osteonecrosis of the femoral head across multiple inheritance models (co-dominant p=0.004; dominant p=0.013) and that CC genotype carriers had statistically elevated serum triglyceride levels (p=0.011). PPARG's role in lipid partitioning — directing fatty acids toward storage vs. oxidation — is a plausible mechanistic bridge between the variant and both ectopic lipid accumulation in bone marrow and circulating triglycerides.

Gene-environment interaction analyses have further identified rs2920502 as a participant in multi-locus models⁶⁶ multi-locus models
Qian et al. 2018 (PMID 29266977) and Zhu et al. 2019 (PMID 30793973) using MB-MDR analysis in 1,591 Chinese adults for both hypertension and nonalcoholic fatty liver disease (NAFLD) susceptibility when combined with angiotensin II receptor type 1 (AGTR1) variants. These interactions suggest that rs2920502's metabolic effects extend to blood pressure regulation and hepatic lipid accumulation — conditions downstream of impaired insulin sensitivity.

Practical Implications

The C allele at rs2920502 is most common in East Asian populations (~74% allele frequency) and South Asian populations (~64%), compared to ~31% in Europeans and only ~10% in African populations. Given these frequencies, CC homozygosity affects roughly 8% of the global population (and substantially more in East/South Asian ancestries).

The primary action areas mirror the known biology of impaired PPARG function: monitoring for early insulin resistance, managing body fat accumulation — particularly visceral fat — and tracking triglycerides and blood glucose over time. Because PPARG is the target of thiazolidinedione drugs (pioglitazone, rosiglitazone), clinicians managing type 2 diabetes in C allele carriers should be aware that variants in this locus can influence drug response.

Interactions

rs2920502 sits within the same PPARG locus as the well-studied Pro12Ala variant rs1801282⁷⁷ rs1801282
The best-characterized PPARG variant; Ala allele protective for T2D with OR 0.86 in 60-study meta-analysis. While they are in the same gene, they have independent functional consequences — rs1801282 is a coding missense in exon B while rs2920502 is intronic. Haplotype combinations of multiple PPARG variants likely have additive or compound effects on adipocyte differentiation capacity.

Gene-gene interaction studies consistently point to interactions between PPARG variants (including rs2920502) and AGTR1 (angiotensin II type 1 receptor) variants in determining metabolic syndrome, hypertension, and NAFLD risk — suggesting that PPARG's metabolic influence is amplified by renin-angiotensin system tone.

The TRIB1 gene¹¹ TRIB1 gene
tribbles pseudokinase 1, a regulatory scaffold protein expressed predominantly in the liver sits at one of the most replicated triglyceride loci in the human genome. Despite encoding a pseudokinase — a protein that resembles a kinase but lacks catalytic activity — TRIB1 has a powerful indirect effect on blood fat levels through its role in controlling hepatic lipid production. The rs2954021 variant, located near the TRIB1 gene on chromosome 8q24, was first identified in a landmark 2008 Nature Genetics GWAS and has since been replicated across dozens of studies and hundreds of thousands of participants.

The Mechanism

TRIB1 acts as a scaffold protein that recruits the COP1 E3 ubiquitin ligase²² COP1 E3 ubiquitin ligase
an enzyme complex that tags proteins for destruction to its substrates, most importantly C/EBPα³³ C/EBPα
CCAAT/enhancer binding protein alpha, a transcription factor that controls the expression of enzymes involved in fatty acid and glucose metabolism in the liver. By promoting C/EBPα degradation, TRIB1 modulates the activity of genes driving de novo lipogenesis⁴⁴ de novo lipogenesis
the liver's process of converting carbohydrates and glucose into triglycerides for storage or export as VLDL particles.

The rs2954021 variant is located in the regulatory region near TRIB1 and is thought to alter the level or timing of TRIB1 expression in hepatocytes. G allele carriers show higher circulating triglycerides and altered LDL levels, consistent with increased hepatic VLDL output. The A allele, while not the major triglyceride risk allele, is strongly associated with elevated liver enzymes (ALT and alkaline phosphatase) and increased susceptibility to nonalcoholic fatty liver disease⁵⁵ nonalcoholic fatty liver disease
NAFLD, the accumulation of excess fat in liver cells not caused by alcohol. This dual-allele risk pattern reflects the complexity of hepatic lipid handling: too much triglyceride export (G allele) raises cardiovascular risk, while impaired export or increased lipid accumulation (A allele) drives liver damage.

The Evidence

The TRIB1 locus was independently discovered by two GWAS published simultaneously in Nature Genetics in 2008 — Kathiresan et al. (8,816 discovery + 18,554 replication subjects)⁶⁶ Kathiresan et al. (8,816 discovery + 18,554 replication subjects)
Six new loci associated with blood LDL cholesterol, HDL cholesterol or triglycerides in humans and Willer et al. (8,816 subjects)⁷⁷ Willer et al. (8,816 subjects)
Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Both studies identified 8q24 near TRIB1 as a novel triglyceride locus, and the association has been replicated in every major subsequent lipid GWAS.

The Global Lipids Genetics Consortium (2013)⁸⁸ Global Lipids Genetics Consortium (2013)
Discovery and refinement of loci associated with lipid levels — the largest lipid GWAS at the time, with over 100,000 participants confirmed TRIB1 as one of the robustly replicated triglyceride loci. The Waterworth et al. (2010) study of 17,723 participants⁹⁹ Waterworth et al. (2010) study of 17,723 participants
showed TRIB1 associations with both lipid traits and coronary artery disease risk, establishing the cardiovascular relevance of elevated triglycerides at this locus.

A large GWAS of 61,089 individuals found the rs2954021-A allele was associated with elevated ALT (p=5×10⁻⁹, beta 1.6%) and alkaline phosphatase (p=2×10⁻¹³, beta 1.4%), implicating TRIB1 in liver cell stress independent of the circulating lipid effects. A Japanese case-control study¹⁰¹⁰ Japanese case-control study
540 NAFLD cases and 1,012 controls found the A allele significantly associated with nonalcoholic fatty liver disease (p=4.5×10⁻⁵), and a 2023 NAFLD GWAS meta-analysis¹¹¹¹ 2023 NAFLD GWAS meta-analysis
66,814 imaging samples confirmed TRIB1 as one of 17 validated NAFLD loci, mechanistically linked to hepatic de novo lipogenesis via glucose metabolism pathways.

Practical Actions

The triglyceride-raising effect of the G allele is meaningfully modulated by diet and lifestyle. Triglyceride levels are among the most diet-responsive of all lipid parameters: refined carbohydrates, sugar, and alcohol are the primary dietary drivers of elevated triglycerides, often more so than dietary fat. G allele carriers benefit substantially from limiting added sugars and refined carbohydrates, moderating alcohol, and increasing omega-3 fatty acid intake (EPA and DHA from fatty fish or fish oil supplements have established triglyceride-lowering effects at doses of 2–4 g/day). Aerobic exercise also directly lowers triglycerides by increasing lipoprotein lipase activity.

For A allele homozygotes with elevated liver enzymes or a family history of fatty liver disease, limiting fructose (a key substrate for hepatic de novo lipogenesis), moderating alcohol strictly, and prioritizing weight management are the most impactful interventions. Baseline measurement of liver enzymes (ALT, AST, GGT) and a fasting lipid panel provides essential context for tracking whether dietary changes are improving liver and lipid health.

Interactions

TRIB1 rs2954021 acts within the broader hepatic lipid metabolism network. GCKR rs1260326 (glucokinase regulatory protein) is a well-established pathway partner that also modulates hepatic triglyceride production — GCKR and TRIB1 variants show independent effects and may compound. APOB rs693 and SORT1 rs12740374 are other LDL-related loci that can combine with TRIB1 effects on atherogenic lipoprotein particles. Carriers of multiple triglyceride-raising variants at these loci face a cumulative lipid burden that warrants a broader lipid panel (including direct LDL measurement and ideally ApoB quantification) rather than standard total cholesterol screening.

Your cells wage a continuous war against entropy. Every day, ultraviolet radiation, reactive oxygen species, replication errors, and jumping genetic elements called retrotransposons threaten the integrity of your DNA. SIRT6 — a NAD+-dependent enzyme — sits at the center of this defense, coordinating DNA double-strand break repair, telomere maintenance, retrotransposon silencing, and metabolic regulation. How well your cells wage this war is partly determined by how much SIRT6 your genome produces, and rs350845 is one of the key regulatory switches.

The Mechanism

rs350845 lies within an intron of the SIRT6 gene on chromosome 19p13.3. Although it does not change the SIRT6 protein sequence, it functions as a cis-acting expression quantitative trait locus (eQTL)¹¹ cis-acting expression quantitative trait locus (eQTL)
a genetic variant that influences how much of a nearby gene is transcribed into mRNA — specifically, the A allele increases SIRT6 transcription across at least 18 tissue types. Carriers of one or two A alleles produce measurably more SIRT6 protein than GG individuals.

SIRT6 requires NAD+²² NAD+
nicotinamide adenine dinucleotide, a coenzyme that declines with age and is the substrate that powers all sirtuin activity as a cofactor to perform two distinct enzymatic reactions: histone deacetylation (removing acetyl marks from histones H3K9 and H3K56 to compact chromatin at DNA break sites and telomeres) and mono-ADP ribosylation (chemically tagging proteins like PARP1 and KAP1 to recruit repair machinery and silence retrotransposons).

When SIRT6 levels are high — as in A-allele carriers — these two functions operate more robustly:

• DNA double-strand break repair: SIRT6 stabilizes DNA-PK and recruits repair factors within seconds of a break occurring. Higher expression means more rapid response to genotoxic insults.
• LINE1 retrotransposon silencing: SIRT6 mono-ADP ribosylates KAP1, which in turn recruits HP1α to package LINE1 elements into condensed, transcriptionally silent heterochromatin (Van Meter et al., Nature Communications 2014)³³ (Van Meter et al., Nature Communications 2014). During aging, SIRT6 becomes depleted from these loci and LINE1s reactivate — driving inflammation and genomic instability. GG individuals, producing less baseline SIRT6, may reach this depletion threshold earlier.
• Telomere maintenance: SIRT6 deacetylates H3K9 at telomeric chromatin, stabilizing the protective cap structure. Insufficient SIRT6 causes telomere uncapping and chromosomal end-joining.

The Evidence

The primary human evidence for rs350845 comes from a 2022 study of 450 Ashkenazi Jewish (AJ) centenarians and 550 AJ controls (Simon et al., EMBO Journal 2022)⁴⁴ (Simon et al., EMBO Journal 2022). The A allele was present in 17.2% of centenarian chromosomes compared to 12.6% in controls (p = 0.009), a nominally significant enrichment replicated against gnomAD reference frequencies (p = 0.007). The same study noted that rs350845 is in near-perfect linkage disequilibrium (r² > 0.98) with rs350843 and rs350846, which also upregulate SIRT6 — all three eQTLs are effectively measuring the same longevity signal.

The causal link between higher SIRT6 and longer life is robustly supported by animal models. SIRT6 transgenic male mice showed 14.5% mean lifespan extension with reduced IGF1 signaling (Kanfi et al., Nature 2012)⁵⁵ (Kanfi et al., Nature 2012). A later study achieved lifespan extension in both sexes by restoring energy homeostasis in aged animals, with SIRT6 overexpression enhancing hepatic NAD+ synthesis and maintaining glucose output through improved gluconeogenic substrate utilization (Roichman et al., Nature Communications 2021)⁶⁶ (Roichman et al., Nature Communications 2021). Across mammalian species, SIRT6 DNA double-strand break repair efficiency correlates strongly with maximum lifespan — longer-lived species simply have more active SIRT6.

A separate rs350845 association was reported for Parkinson's disease risk in a Hungarian cohort (Torok et al., Scientific Reports 2021)⁷⁷ (Torok et al., Scientific Reports 2021), but the finding was not significant after false discovery rate correction and should be considered exploratory.

The evidence level for rs350845 is moderate: the longevity association is nominally significant in one well-designed cohort and is mechanistically coherent, but replication in non-Ashkenazi populations and larger genome-wide studies is needed to establish it at the strong level.

Practical Implications

The core implication of this SNP is about NAD+ sufficiency and DNA-damage avoidance. SIRT6 is NAD+-dependent, and NAD+ declines ~50% by age 60 in humans. GG individuals, who already produce less baseline SIRT6, are more exposed to the functional consequences of this decline. Supporting NAD+ levels with precursors and protecting against unnecessary DNA damage (ionizing radiation, genotoxic chemicals, tobacco carcinogens) become especially relevant for GG carriers.

For AG and AA carriers, the A allele provides partial to full upregulation of SIRT6 expression — but this benefit still depends on adequate NAD+ availability to keep the enzyme active. All genotypes benefit from NAD+ support, but the priority is highest for GG.

Interactions

rs350845 is in high LD with rs350843 and rs350846, which tag the same SIRT6-upregulating haplotype. These are not independent signals.

rs107251 is a separate SIRT6 intronic variant (not in LD with rs350845) associated with >5-year mean survival advantage for CC and CT carriers vs TT in an Iowa aging cohort (TenNapel et al., PLOS ONE 2014)⁸⁸ (TenNapel et al., PLOS ONE 2014). Individuals who carry the protective allele at both rs350845 (A) and rs107251 (C) likely enjoy additive SIRT6-related genomic stability benefits, though formal compound analysis has not been published.

rs12696304 (TERC) influences telomere length through the telomerase RNA component. Since SIRT6 also regulates telomere chromatin stability, GG carriers at rs350845 who also carry G alleles at rs12696304 face a double burden of reduced telomere protection: less SIRT6-mediated heterochromatin at telomere ends AND shorter baseline telomere length from reduced telomerase activity. Both variants are in the longevity category and their interaction is mechanistically plausible, though specific compound data are lacking.

For the supervisor: a compound action covering rs350845 GG + rs12696304 GG would target individuals with dual telomere vulnerability — reduced SIRT6-mediated telomere chromatin stability AND reduced telomerase RNA activity. Combined recommendation: prioritize NAD+ precursor supplementation to maximize SIRT6 activity and emphasize high-MUFA dietary patterns (CORDIOPREV evidence) plus monitoring telomere-associated biomarkers. Evidence level: emerging (mechanistically coherent, no published compound study).